Latest News and Press Releases
Want to stay updated on the latest news?
-
HCW Biologics signed license agreement with WY Biotech
-
Press release for Q3 2024 business highlights and financial results
-
Results of Q2 2024, including settlement of long-running arbitration.
-
Results of Q2 2024, including settlement of long-running arbitration.
-
Earning release for Q1 2024
-
Q4 and Year End Earnings Release and Business Highlights
-
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
-
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
-
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
-
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...